PT - JOURNAL ARTICLE AU - Selvaraj, Vijairam AU - Khan, Mohammad Saud AU - Dapaah-Afriyie, Kwame AU - Finn, Arkadiy AU - Bavishi, Chirag AU - Lal, Amos AU - Mylonakis, Eleftarios TI - Tocilizumab in hospitalized patients with COVID-19: A meta analysis of randomized controlled trials AID - 10.1101/2021.03.23.21254054 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.23.21254054 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21254054.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21254054.full AB - Background To date, only dexamethasone has been shown to reduce mortality in COVID-19 patients. Tocilizumab has been recently added to the treatment guidelines for hospitalized COVID-19 patients, but data remains conflicting.Methods Electronic databases such as MEDLINE, EMBASE and Cochrane central were searched from March 1, 2020, until February 28th, 2021, for randomized controlled trials evaluating the efficacy of tocilizumab in hospitalized COVID-19 patients. The outcomes assessed were all-cause mortality at 28 days, mechanical ventilation, and time to discharge.Results Eight studies (with 6,311 patients) were included in the analysis. In total, 3,267 patients received tocilizumab, and 3,044 received standard care/placebo. Pooled analysis showed a significantly decreased risk of all-cause mortality at 28 days (RR 0.90, 95% CI 0.83-0.97, p=0.009) and progression to mechanical ventilation (RR 0.79, 95% CI 0.70-0.90, p=0.0002) in the tocilizumab arm compared to standard therapy or placebo. In addition, there was a trend towards improved median time to hospital discharge (RR 1.18, 95% CI 1.05-1.34, p=0.007).Conclusions Tocilizumab therapy improves outcomes of mortality and need for mechanical ventilation, in hospitalized patients with COVID-19 infection compared with standard therapy or placebo. Our findings suggest the efficacy of tocilizumab therapy in hospitalized COVID-19 patients and strengthen the concept that tocilizumab is a promising therapeutic intervention to improve mortality and morbidity in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was obtainedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available within the manuscriptBACCBoston Area COVID-19 ConsortiumRCT-TCZ-COVID-19Randomized Controlled Trial-Tocilizumab-COVID-19CORIMUNO-TOCI-1Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 PatientsEMPACTAEvaluating Minority Patients with ActemraREMAP-CAPRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired PneumoniaRECOVERYRandomised Evaluation of COVID-19 TherapyMEDLINEMedical Literature Analysis and Retrieval System OnlineEMBASEExcerpta Medica database